Product Description
Mechanisms of Action: ADRA1 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: India | Korea | Taiwan
Approved Indications: None
Known Adverse Events: None
Company: Dong-A
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Lower Urinary Tract Symptoms|Prostatic Hyperplasia|Ureteral Calculi|Nephrolithiasis|Kidney Calculi|Ureterolithiasis
Phase 3: Pain Unspecified|Lower Urinary Tract Symptoms|Ureterolithiasis|Ureteral Calculi|Prostatic Hyperplasia
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
ChiCTR-IPR-15006185 | N/A |
Recruiting |
Ureteral Calculi|Overactive Bladder |
2017-09-30 |
|
SNUBH-URO-2012-03 | P3 |
Completed |
Ureterolithiasis|Ureteral Calculi |
2015-08-01 |
|
SNUH-URO-2012-04 | P3 |
Completed |
Pain Unspecified |
2015-06-01 |
|
SMC2013-08-066 | P4 |
Unknown status |
Ureteral Calculi|Nephrolithiasis|Kidney Calculi|Ureterolithiasis |
2015-02-01 |